<DOC>
	<DOCNO>NCT01346501</DOCNO>
	<brief_summary>The main objective study determine ability maintain response discontinuation adalimumab treatment secondary objective determine radiographic progression participant participate study , include percentage display minimal progression .</brief_summary>
	<brief_title>Special Investigation Patients With Rheumatoid Arthritis ( HOPEFUL III Study ) , Follow-up Survey Study P12-069</brief_title>
	<detailed_description>This two-arm , multi-center , Post Marketing Observational Study ( PMOS ) conduct Japanese participant Rheumatoid Arthritis ( RA ) continue one year observational period study P12-069 ( HOPEFUL II study ; NCT01163292 ) provide informed consent participate study P12-707 ( HOPEFUL III study ; NCT01346501 ) , completion study M06-859 ( HOPEFUL I study ; NCT00870467 ) . The study P12-707 provide additional two year observation participant participate study P12-069 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participants RA continue one year observational period study P12069 provide informed consent participate study P12707 . Participants RA use biological agent adalimumab one year observational period study P12069 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>